Season Finale (PART 2 of 2): Top 20 Hair Research Studies of 2022

The season finale summarizes the top 20 studies of the 2022 calendar year. This episode addresses studies in hair shedding, scarring alopecia, seborrheic dermatitis and hair straighteners (studies 12 to 20). Studies 1 to 11 are found in Part 1 (season 3 episode 9)     STUDIES IN HAIR SHEDDING/TELOGEN EFFLUVIUM/ COVID19   STUDY 12: Muller-Ramos P et al. Post-COVID-19 hair loss: prevalence and associated factors among 5,891 patients. Int J Dermatol 2022 Jan 26.   STUDY 13: Anna Carolina Miola et al. Early-onset effluvium secondary to COVID-19: Clinical and histologic characterization. J Am Acad Dermatol. 2022   STUDY 14: Mazeto IFS et al. Ultrastructural evidence for anagen hair follicle infection with SARS-CoV-2 in early-onset COVID-19 effluvium. J Eur Acad Dermatol Venereol. 2022 Jun 20.     STUDIES IN SCARRING ALOPECIA   STUDY 15: Dubin C et al. Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement. J Am Acad Dermatol. 2022 Mar;86(3):551-562. doi: 10.1016/j.jaad.2021.05.016   STUDY 16: Jamerson et al. Gene expression profiling suggests severe, extensive central centrifugal cicatricial alopecia may be both clinically and biologically distinct from limited disease subtypes Exp Dermatol. 2022 Jan   STUDY 17: Joshi TP et al. Prevalence of lichen planopilaris in the United States: A cross-sectional study of the All of Us research program. JAAD Int. 2022 Jun 13;8:69-70.   STUDY 18: Joshi et al. Comorbidities associated with lichen planopilaris: a case-control study using the All of Us database. Int J Dermatol. 2022 Oct 2.     STUDIES  IN VARIOUS TOPICS   STUDY 19: Chang CJ et al. Use of Straighteners and Other Hair Products and Incident Uterine Cancer. J Natl Cancer Inst. 2022 Oct 17;djac165.   STUDY 20: Ying-Yi Lu et al. Impact of seborrheic dermatitis on osteoporosis risk: A population-based cohort study. J Dermatol. 2022 Sep 12.     STUDIES IN PART 1 of PODCAST  STUDIES IN AGA STUDY 1: Qui Y et al. Systematic Review and Meta-analysis of the Association Between Metabolic Syndrome and Androgenetic Alopecia. Acta Derm Venereol. 2022 Feb 8;102:adv00645 STUDY 2: Cao L et al. Nailfold capillaroscopy alterations in androgenetic alopecia: A cross-sectional study. Indian J Dermatol Venereol Leprol. 2022 Feb 28;1-7. doi: 10.25259/IJDVL_714_2021. STUDY 3: Sanabria et al. Prospective cardiovascular evaluation with 24-h Holter and 24-h ambulatory blood pressure monitoring in men using 5 mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2022 May 18;   STUDY 4: Jimenez-Cauhe J et al. Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil. J Am Acad Dermatol. 2022 Dec;87(6):e235-e237.   STUDY 5: Gupta AK et al. Relative Efficacy of Minoxidil and the 5-alpha Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatol. 2022 Feb 2:e215743.   STUDY 6: Gupta AK and Bamimore M. Platelet-Rich Plasma Monotherapies for Androgenetic Alopecia: A Network Meta-Analysis and Meta-Regression Study. J Drugs Dermatol. 2022 Sep 1;21(9):943-952.   STUDY 7: Gupta AK et al. There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses. Skin Appendage Disord. 2022 Sep; 8(5): 355–36   STUDY 8: Klein E et al. Comparing combination low-dose oral minoxidil and topical minoxidil with oral minoxidil alone for the treatment of non-scarring alopecia; a retrospective chart review. J Cosmet Dermatol. 2022 Jun 1.   STUDY 9: Liang  X et al. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial. Front Med (Lausanne). 2022 Jul 11;9:905140.   STUDIES IN ALOPECIA AREATA     STUDY 1